Colorectal carcinoma metastases: Detection with In-111-labeled monoclonal antibody CCR 086

H. H. Abdel-Nabi*, G. Levine, L. M. Lamki, J. L. Murray, W. N. Tauxe, A. N. Shah, Y. Z. Patt, R. J. Doerr, H. A. Klein, J. Gona, M. J. Rosenblum, M. J. Unger, L. M. Smith, S. A. Schweighardt, E. B. Merchant

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


A phase I/II clinical trial with indium-111-labeled antimucin murine monoclonal antibody (MoAb) CCR 086 was conducted. Seventeen patients with histologically proved colorectal carcinoma and known metastatic disease underwent external scintigraphy after administration of 5.5 mCi (203.5 MBq) of In-111 CCR 086 at doses of 5 and 20 mg. Of 25 known lesions, 17 were detected (sensitivity, 68%). The smallest detected lesion in the lung was 1 cm and in the liver was 1.5 cm. The serum half-life of In-111-labeled CCR 086 MoAb was approximately 64 hours. The formation of human antimouse antibody (HAMA) was detected in the serum of four of five patients who received 20 mg of MoAb. No HAMAs were detected in four patients receiving 5 mg of MoAb. No side effects were encountered. Because of effective detection of liver and lung metastases with lower doses (5-20 mg) of CCR 086 conjugated with In-111, further investigations are warranted to assess clinical and therapeutic potentials of CCR 086 in the management of colorectal cancer.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
Issue number1
Publication statusPublished - 1990


  • Colon, neoplasms
  • indium, radioactive
  • liver neoplasms, secondary
  • liver, radionuclide studies
  • lung neoplasms, secondary
  • lung, radionuclide studies
  • monoclonal antibodies
  • rectum, neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Colorectal carcinoma metastases: Detection with In-111-labeled monoclonal antibody CCR 086'. Together they form a unique fingerprint.

Cite this